Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Mato, Sara; Carita, Lorenzo; Colmenero, Ariadna; Andrés, Mara; Balague, Olga; Andion, Maitane; Astigarraga, Itziar; Celis, Veronica; Mendoza, Carmen; Guerra-García, Pilar; Valero, Lorena; Galera-Miñarro, Ana-María; Tallon, María; Pol, Melina; Castrejon-de-Anta, Natalia; Frauenfeld, Leónie; García, Noelia; Campo, Elias; Salaverria, Itziar; Verdu-Amoros, Jaime

RICSMUR Principal
→
02. Servicio Murciano de Salud (SMS)
→
02.01. Área de Salud I Murcia Oeste
→
02.01.01. Investigación y comunicación científica
→
Ver ítem

dc.contributor.author	Mato, Sara
dc.contributor.author	Carita, Lorenzo
dc.contributor.author	Colmenero, Ariadna
dc.contributor.author	Andrés, Mara
dc.contributor.author	Balague, Olga
dc.contributor.author	Andion, Maitane
dc.contributor.author	Astigarraga, Itziar
dc.contributor.author	Celis, Veronica
dc.contributor.author	Mendoza, Carmen
dc.contributor.author	Guerra-García, Pilar
dc.contributor.author	Valero, Lorena
dc.contributor.author	Galera-Miñarro, Ana-María
dc.contributor.author	Tallon, María
dc.contributor.author	Pol, Melina
dc.contributor.author	Castrejon-de-Anta, Natalia
dc.contributor.author	Frauenfeld, Leónie
dc.contributor.author	García, Noelia
dc.contributor.author	Campo, Elias
dc.contributor.author	Salaverria, Itziar
dc.contributor.author	Verdu-Amoros, Jaime
dc.date.accessioned	2026-03-06T14:20:17Z
dc.date.available	2026-03-06T14:20:17Z
dc.date.issued	2025-05
dc.identifier.citation	Mato S, Carità L, Colmenero A, Andrés M, Balagué O, Andión M, et al. Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents. Br J Haematol. mayo de 2025;206(5):1390-6. doi:10.1111/bjh.20012
dc.identifier.issn	0007-1048
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/24800
dc.description.abstract	The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).
dc.language.iso	eng
dc.publisher	WILEY
dc.rights	Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/deed.es
dc.subject.mesh	Humans
dc.subject.mesh	Adolescent
dc.subject.mesh	Child
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Child, Preschool
dc.subject.mesh	Lymphoma, B-Cell/genetics/therapy/mortality
dc.subject.mesh	Rituximab/therapeutic use/administration & dosage
dc.subject.mesh	Mutation
dc.subject.mesh	Tumor Suppressor Protein p53/genetics
dc.subject.mesh	Recurrence
dc.title	Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	40011029
dc.relation.publisherversion	https://onlinelibrary.wiley.com/doi/10.1111/bjh.20012
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.identifier.doi	10.1111/bjh.20012
dc.journal.title	British Journal of Haematology
dc.identifier.essn	1365-2141